|
Speciality Spotlight
Pharmacokinetics
of Ceftazidime
-
BJ Angus, MD Smith, Y Suputtamongkol, H Mattie, AL Walsh, V Wuthiekanum, W Chaowagul & NJ White. (Faculty of Tropical Medicne, Mahidol University, Nuffield Dept of Clinical Medicine, Oxford Univ, Oxford, UK, Dept of Infectious Diseases, Univ Hospital, Leiden, The Netherlands, Dept.of Medicine, Sappasitprasong Hosp, Ubon Ratchatani, Thailand & Dept of Medicien, Siriraj Hosp, Bangkok, Thailand).
Pharmacokinetic-pharmacodyamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.
Br.J Clin Pharmacol, 49; 445-452.
The continuous infusion gives higher and more effective blood levels of Ceftazidime than intermittent bolus injection. This is very important in septicaemic patients.
Pharmacokinetics
-
D. Turck, G Heinzel & G. Luik, (Department of Pharmacokinetics and Drug Metabolism, Boehringer Ingelheim Pharma, Germany).
Steady-state pharmacokinetics of lithium in healthy volunteers receiving concomitant meloxicam.
Br.J Cl.Pharm, September 2000, 50(3), 197-204
Summary : Lithium is used in treatment of unipolar and bipolar depression and has a narrow therapeutic range. A slight increase in serum concentration may result in serious adverse effects.
Meloxicam (15mg) moderately increased the plasma concentration of lithium in healthy volunteers – probably of low clinical relevance. Nevertheless, lithium plasma concentration should be monitored in patients receiving concomitant meloxicam and lithium therapy.
-
Zhen Ren, Storm Floten, et al (Cardiovascular Research, Albert Starr Academic Center for Cardiac Surgery, Providence St Vincent Hospital, Portland, USA and Division of Cardiothoracic Surgery, Department of Surgery, The Chinese University of Hong Kong, China).
Effect of Potassium Channel opener KRN 4884 on human conduit arteries used as coronary bypass grafts.
Br. J Clin.Pharmacol, 50(2), August 2000, p. 154-160.
Use of vasodilators in coronary artery bypass grafting has become an important issue regarding vasospasm of bypass graft. Many vasodilators have been used in patients undergoing coronary artery bypass grafting. KRN 4884, is a novel ATP-sensitive potassium channel opener. In this study, effect of this drug is studied on human internal mammary artery, to provide information on possible clinical use of this drug in preventing and relieving vasospasm of arterial grafts in coronary artery bypass grafting.
The present study suggests that KRN4884 has marked vasorelaxant effects in human IMA contracted by a variety of vasoconstrictors. These effects are vasoconstrictor – selective with greater potency to NA, ANG II or 5HT than to ET-1. This vasorelaxant effect may be useful in coronary artery bypass surgery for prevention and treatment of vasospasm in the graft.
